Alcon Acquired by Novartis
On December 15, 2010, Novartis (NYSE: NVS) agreed to acquire the remaining shares of Alcon, Inc. (NYSE: ACL) it doesn't currently own for $168 per share.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
View Older Stories
-
Alcon to Debut TOTAL30 for Astigmatism, Dry Eye and Ocular Health Innovations at SECO 2023
-
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business
-
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business
-
Alcon to Celebrate 75 Years of Brilliance and Showcase Contact Lens Innovations at #Academy22
-
Alcon (ALC) Acquires Aerie Pharmaceuticals (AERI) for $15.25/sh or $770M
-
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
-
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
-
Football Star Cooper Kupp Encourages Eye Allergy Sufferers to Find the Right Tool for the Job with Pataday
-
Actress Kate Walsh Teams Up with Eye Care Leader Alcon to Inspire Millions of Dry Eye Sufferers to Make Every Look Count
-
Actress Kate Walsh Teams Up with Eye Care Leader Alcon to Inspire Millions of Dry Eye Sufferers to Make Every Look Count
-
RBC Capital Sees Positive Read-Through to Bausch Health Companies (BHC) from Alcon's (ALC) EPS
-
Alcon Completes Acquisition of Ivantis, Inc., Bringing Hydrus Microstent into Its Global Surgical Portfolio
-
Alcon Continues Its Successful Rollout of PRECISION1 Daily Disposable Contact Lenses, Now Available in Key Markets Throughout Latin America, Asia & Europe
-
Alcon Reports Third Quarter 2021 Results
-
Alcon Reports Third Quarter 2021 Results
-
Alcon (ALC) to Acquire Ivantis for $475M Upfront
-
Alcon to Acquire Ivantis, Inc. and its Hydrus Microstent for Surgical Glaucoma, Strengthening Global Ophthalmology Portfolio
-
Alcon to Acquire Ivantis, Inc. and its Hydrus Microstent for Surgical Glaucoma, Strengthening Global Ophthalmology Portfolio
-
Alcon #Academy21 Program to Showcase TOTAL30, Other Innovations that Meet Critical Patient and Practice Needs
-
Alcon Celebrates World Sight Day 2021 in Communities Worldwide with Programs for Improved Access to Eye Care
-
Alcon Reports Second Quarter 2021 Results
-
Alcon Reports Second Quarter 2021 Results
-
Alcon to Showcase Vision Care Innovation, Including Clinical Data for its Forthcoming Reusable Monthly Lens TOTAL30, at BCLA 2021
-
Alcon to Showcase Vision Care Innovation, Including Clinical Data for its Forthcoming Reusable Monthly Lens TOTAL30, at BCLA 2021
-
Alcon Reports First Quarter 2021 Results
-
Alcon Reports First Quarter 2021 Results
-
Alcon (ALC) to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
-
Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
-
Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
-
Alcon Inc. (ALC) Capital Markets Day Is Likely a Positive Catalyst - Jefferies
-
UPDATE: BTIG Upgrades Alcon Inc. (ALC) to Buy
-
Alcon Reports Fourth Quarter and Full Year 2020 Results
-
Alcon Reports Fourth Quarter and Full Year 2020 Results
-
Alcon Announces Broad Retail Availability of Pataday Once Daily Relief Extra Strength in the U.S.
-
Alcon Announces Broad Retail Availability of Pataday Once Daily Relief Extra Strength in the U.S.
-
Alcon Launches PRECISION1 for Astigmatism Contact Lenses in the U.S.
-
Alcon Launches PRECISION1 for Astigmatism Contact Lenses in the U.S.
-
Alcon Reports Third Quarter 2020 Results
-
Alcon Reports Third Quarter 2020 Results
-
Alcon U.S. PRECISION1 Launch Momentum Bolstered by Strong Programs, Differentiated On-Eye Performance
-
Alcon U.S. PRECISION1 Launch Momentum Bolstered by Strong Programs, Differentiated On-Eye Performance
-
Alcon Celebrates World Sight Day 2020 and Continues Commitment to Improving Worldwide Access to Eye Care
-
Alcon to Showcase Innovations at #Academy20 that Support Recovery and Growth for Eye Care Practices
-
Alcon and Actress Katherine McNamara Encourage Consumers to See What Happens with PRECISION1® Contact Lenses
-
Alcon Reports Second Quarter 2020 Results
-
Alcon Reports Second Quarter 2020 Results
-
Alcon Survey Shows More Screen Time Causing Consumer Concern About Eye Health, Increasing Symptoms of Dry Eye
-
Alcon Survey Shows More Screen Time Causing Consumer Concern About Eye Health, Increasing Symptoms of Dry Eye
-
Alcon (ALC) Announces FDA Approval of the OTC Switch of Pataday Once Daily Relief Extra Strength
-
Alcon Announces FDA Approval of the OTC Switch of Pataday Once Daily Relief Extra Strength

